Pfizer

C3441021 | TALAPRO-2

NCT03395197

JCP061

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)

Status:

Recruiting

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

DDR

Investigational

Product

Talazoparib

PARP inhibitor (p.o.)

Treatment Arms

o Experimental: Combination arm

o Active Comparator: Monotherapy arm